Syndax's New Patient Intake Narrative Gets a Second Chance to Hold

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Syndax typically reports earnings after market close, meaning Day 0 reflects pre-announcement anticipation while Day +1 captures the market's first full reaction to results.

Historical price behavior reveals substantial volatility around earnings, with the stock averaging an 11.26% absolute move on Day +1 and a 13.67% intraday range—significantly higher than typical biotech earnings reactions. The most dramatic moves occurred in Q3 2025 (November 2025), when shares surged 11.56% on Day +1 with a 19.26% intraday range, and in Q2 2025 (August 2025), which saw a 21.10% Day +1 rally. Conversely, the Q1 2026 report (April 2026) triggered a sharp -10.83% Day +1 decline despite a modest 3.88% Day 0 gain, illustrating how initial reactions can reverse dramatically.

The Day 0 moves average just 1.96%, suggesting limited pre-announcement positioning, but the 5.93% average Day 0 range indicates significant intraday volatility as traders position ahead of the after-hours release. Recent quarters show a pattern of positive Day +1 reactions following beats (Q3 2025's +11.56%, Q1 2026's +5.03% after the 18.64% earnings beat) and sharp selloffs following misses (Q1 2026's -10.83% after initially rising, Q4 2024's -21.59% decline). Given the most recent quarter's -22.22% earnings miss, investors should prepare for potentially elevated volatility, particularly if Q3 results surprise in either direction on commercial execution or guidance.

Part 2.2: Options Market Expected Move

The options market is pricing an 11.83% expected move through the November 20 expiration (21 days out), which sits slightly above the 11.26% average Day +1 move but below the 13.67% average Day +1 range seen historically. This suggests options traders are anticipating elevated but not extreme volatility—consistent with recent earnings patterns but not pricing in the outsized 19-21% moves seen in some prior quarters.

Part 3: What Analysts Are Saying

Analyst sentiment on Syndax remains overwhelmingly bullish despite recent stock weakness, with 13 of 14 analysts rating shares a Strong Buy and the remaining analyst at Hold—no sell ratings exist. The average price target of $37.00 implies 171% upside from the current $13.65 price, reflecting conviction that commercial execution will eventually drive substantial appreciation. Price targets range from a low of $23.00 (68% upside) at Bank of America Securities to a high of $57.00 (318% upside) at Citi, illustrating divergent views on the company's long-term revenue potential.

The consensus rating of 4.86 out of 5.0 places SNDX among the most highly rated biotechs, with the average recommendation unchanged over the past month at 4.86, indicating stable sentiment despite the stock's technical deterioration. This stability is captured in the sentimentTrend reading of unchanged—analysts have maintained their bullish stance even as shares have declined below all major moving averages, suggesting conviction that current weakness represents a buying opportunity rather than fundamental deterioration.

Recent analyst actions show modest price target adjustments while maintaining buy ratings. UBS lowered its target from $37 to $33 in October following the MAXPIRe trial miss, while Bank of America reduced its target from $26 to $23, reflecting tempered near-term expectations. However, Citi, Barclays, and H.C. Wainwright all maintained their targets at $57, $37, and $38 respectively, emphasizing confidence in the commercial trajectory. The wide target range ($23-$57) reflects uncertainty around pipeline success and the pace of commercial ramp, but the heavily skewed buy ratings indicate analysts believe current levels significantly undervalue the company's approved product portfolio and market opportunity.

Part 4: Technical Picture

The Barchart Technical Opinion shows maximum bearish conviction heading into earnings, with a 100% Sell signal that has remained unchanged over the past week and month. This consistent negative reading reflects sustained technical deterioration as shares have broken below all major moving averages and established a clear downtrend from the 52-week high of $25.59 to the current $13.65 level.

Timeframe Analysis:

• Short-term (100% Sell): Maximum sell signal indicates severe near-term downside momentum with no technical support
• Medium-term (100% Sell): Persistent weakness across the intermediate timeframe confirms the downtrend is well-established, not just a short-term dip
• Long-term (100% Sell): Bearish long-term signal suggests the stock has lost its structural uptrend and faces significant technical repair work

Trend Characteristics: The combination of Maximum strength and Strongest direction creates an extremely hostile technical environment heading into earnings, suggesting any disappointment could trigger accelerated selling while even positive results may face resistance from entrenched bearish momentum.

Shares currently trade at $13.65, positioned below the 5-day moving average of $13.81, above the 10-day average of $13.55, but below all longer-term averages including the 20-day ($14.61), 50-day ($17.18), 100-day ($18.94), and 200-day ($20.23). This configuration shows the stock briefly bounced above its 10-day average but remains trapped well below all meaningful resistance levels, with the 20-day average serving as immediate overhead resistance.

The progressive decline in moving averages—from $20.23 (200-day) down to $13.55 (10-day)—illustrates the sustained nature of the selloff, with each timeframe confirming lower highs and lower lows.

Key technical levels to watch include immediate resistance at the 20-day moving average of $14.61, which has capped recent rallies, and the psychologically important $15.00 level. On the downside, the 52-week low of $12.80 sits just 6% below current levels and represents critical support—a break below could trigger stop-loss selling and test the stock's ability to hold double digits. The 79.16% average implied volatility in options reflects elevated uncertainty, while the 11.83% expected move suggests traders are bracing for significant post-earnings price action. The overall technical setup is decidedly cautionary: the unanimous sell signals across all timeframes, positioning below all major moving averages except the 10-day, and proximity to 52-week lows create a challenging backdrop where even solid earnings may struggle to reverse the established downtrend. Bulls need to see not just a beat but also guidance strong enough to break the stock above the 20-day average and begin rebuilding technical momentum.